Kim D H, Yang D H, Hong S Y
Department of Internal Medicine, Soonchunhyang Hospital, Chunan City, Korea.
Korean J Intern Med. 1998 Feb;13(1):33-40. doi: 10.3904/kjim.1998.13.1.33.
Recent reports have suggested that patients treated by CAPD have a relatively increased risk of death compared to patients undergoing HD, although the cause of this discrepancy is poorly understood. Protein malnutrition is an important risk factor in ESRD. Also, amino acid concentrations, for which the physiological function differs from that of protein, may be an independent risk factor in ESRD. There is no doubt concerning the prevalence of low amino acid levels in both HD and CAPD patients. But the difference in plasma amino acid levels between these two groups has not been well defined. The purpose of this study is to compare plasma amino acid levels between patients with ESRD on HD and CAPD.
A cross sectional study of overnight fasting plasma amino acid concentrations was performed on 12 CAPD and 45 HD patients with ESRD, matched by age, sex and body mass index. The levels of individual plasma amino acid and TAA, EAA, NEAA and BCAA were compared for the HD and CAPD groups. In order to measure losses during HD and CAPD, amino acid and protein concentrations were measured from 10 dialysates obtained from 10 HD patients and 12 peritoneal dialysis solutions from 12 CAPD patients.
All of the measured amino acid concentrations were found to be lower in the CAPD group compared to the HD group. Furthermore, the levels of TAA (2017.3 +/- 781.1 vs. 903.3 +/- 316.1 mumole/L), EAA(1201.8 +/- 492.6 vs. 567.6 +/- 223.2 mumole/L), NEAA(815.5 +/- 308.6 vs. 335.7 +/- 100.2 mumole/L); and BCAA (315.0 +/- 146.0 vs. 145.2 +/- 65.0 mumole/L), were all lower in the CAPD group than in the HD group. The protein loss was 2.0 +/- 0.2 g/L in the peritoneal dialysate but was not detectable in the hemodialysates. TAA loss over a one week period was about 61.8 +/- 13.0mmole for the HD group and 38.0 +/- 13.0 mmole for the CAPD group.
Our results show that amino acid concentrations are lower in ESRD patients on CAPD than on HD. It seems likely that protein loss in the peritoneal dialysate is a contributing factor to lowered plasma amino acid concentrations in ESRD patients on CAPD than on HD. We believe that the lowered amino acid concentrations observed in CAPD patients may worsen the clinical outcome compared to HD patients.
近期报告显示,与接受血液透析(HD)的患者相比,接受持续性非卧床腹膜透析(CAPD)治疗的患者死亡风险相对增加,尽管这种差异的原因尚不清楚。蛋白质营养不良是终末期肾病(ESRD)的一个重要风险因素。此外,氨基酸浓度的生理功能与蛋白质不同,可能是ESRD的一个独立风险因素。毫无疑问,HD和CAPD患者中氨基酸水平低的情况普遍存在。但这两组患者血浆氨基酸水平的差异尚未明确界定。本研究的目的是比较HD和CAPD治疗的ESRD患者的血浆氨基酸水平。
对12例CAPD患者和45例HD治疗的ESRD患者进行横断面研究,比较其过夜空腹血浆氨基酸浓度,两组患者在年龄、性别和体重指数方面相匹配。比较HD组和CAPD组个体血浆氨基酸以及总氨基酸(TAA)、必需氨基酸(EAA)、非必需氨基酸(NEAA)和支链氨基酸(BCAA)的水平。为了测量HD和CAPD过程中的损失,检测了10例HD患者的10份透析液和12例CAPD患者的12份腹膜透析液中的氨基酸和蛋白质浓度。
发现CAPD组所有测量的氨基酸浓度均低于HD组。此外,CAPD组的TAA(2017.3±781.1对903.3±316.1微摩尔/升)、EAA(1201.8±492.6对567.6±223.2微摩尔/升)、NEAA(815.5±308.6对335.7±100.2微摩尔/升)和BCAA(315.0±146.0对145.2±65.0微摩尔/升)水平均低于HD组。腹膜透析液中的蛋白质损失为2.0±0.2克/升,但在血液透析液中未检测到。HD组一周内TAA损失约为61.8±13.0毫摩尔,CAPD组为38.0±13.0毫摩尔。
我们的结果表明,CAPD治疗的ESRD患者的氨基酸浓度低于HD治疗的患者。腹膜透析液中的蛋白质损失似乎是导致CAPD治疗的ESRD患者血浆氨基酸浓度低于HD治疗患者的一个因素。我们认为,与HD患者相比,CAPD患者中观察到的氨基酸浓度降低可能会使临床结局恶化。